Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 7/20 | 0.47 |
| ▸ | CNR2 | P34972 | 9/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | CNR1 | P21554 | 2/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12927947 | 0.91 | TTK (0.46) | TTKCNR2CYP2C19RORCCYP3A4 | |
| SCHEMBL140031 | 0.83 | TTK (0.38) | TTKMAPK14 | |
| SCHEMBL104889 | 0.82 | TTK (0.42) | TTKCNR2CNR1 | |
| SCHEMBL137808 | 0.82 | TTK (0.73) | TTK | |
| SCHEMBL135511 | 0.80 | MALT1 (0.36) | TTK | |
| SCHEMBL105613 | 0.76 | TTK (0.36) | TTKCNR2CNR1MAPK14 | |
| SCHEMBL138966 | 0.76 | TTK (0.42) | TTKCNR2CYP2C19CNR1CYP3A4 | |
| SCHEMBL137816 | 0.76 | TTK (0.45) | TTKCYP3A4 | |
| SCHEMBL10282480 | 0.75 | TTK (0.32) | TTKCNR2CNR1 | |
| SCHEMBL104174 | 0.75 | CDK9 (0.33) | TTKCNR2CYP1A2CYP2C19CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2460805-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | Oncotherapy Science, Inc. (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | TTK 6/4885CNR2 1750/4885CYP1A2 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.